Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Diffuse Cystic Metastases in the Lung after Nivolumab Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report

Diffuse Cystic Metastases in the Lung after Nivolumab Treatment in a Patient with Non-Small Cell... Although diffuse cysts in the lung can be found in many diseases, they are uncommon in metastatic lung adenocarcinoma. They are even more unusual after the administration of immune checkpoint inhibitors. A case of lung adenocarcinoma that developed diffuse cysts in the lungs during treatment with nivolumab is reported. The patient was a 60-year-old woman with postoperative recurrent lung adenocarcinoma in mediastinal lymph nodes and pleural dissemination. After first-line treatment with cisplatin, pemetrexed, and bevacizumab, computed tomography (CT) showed disease progression. Treatment was then switched to nivolumab. After 5 courses of nivolumab, CT showed multiple ground-glass nodules in her lungs. After 4 more courses of nivolumab, the ground-glass nodules increased in size, and cystic air spaces appeared in their centers. The patient did not have any symptoms. Laboratory tests showed no evidence of infection or nivolumab-induced pneumonitis. Sialyl Lewis X-i antigen increased, and positron emission tomography showed abnormal uptake of <sup>18</sup>F-fluorodeoxyglucose in these lesions. Considering this evidence, the cystic lesions were diagnosed as multiple lung metastases. Various differential diagnoses should be considered when diffuse cystic lesions are found in the lungs after the administration of immune checkpoint inhibitors. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Case Reports in Oncology Karger

Diffuse Cystic Metastases in the Lung after Nivolumab Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report

Download PDF
5 pages

Loading next page...
 
/lp/karger/diffuse-cystic-metastases-in-the-lung-after-nivolumab-treatment-in-a-rEnMYF1sUN

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 2021 The Author(s). Published by S. Karger AG, Basel
eISSN
1662-6575
DOI
10.1159/000513426
Publisher site
See Article on Publisher Site

Abstract

Although diffuse cysts in the lung can be found in many diseases, they are uncommon in metastatic lung adenocarcinoma. They are even more unusual after the administration of immune checkpoint inhibitors. A case of lung adenocarcinoma that developed diffuse cysts in the lungs during treatment with nivolumab is reported. The patient was a 60-year-old woman with postoperative recurrent lung adenocarcinoma in mediastinal lymph nodes and pleural dissemination. After first-line treatment with cisplatin, pemetrexed, and bevacizumab, computed tomography (CT) showed disease progression. Treatment was then switched to nivolumab. After 5 courses of nivolumab, CT showed multiple ground-glass nodules in her lungs. After 4 more courses of nivolumab, the ground-glass nodules increased in size, and cystic air spaces appeared in their centers. The patient did not have any symptoms. Laboratory tests showed no evidence of infection or nivolumab-induced pneumonitis. Sialyl Lewis X-i antigen increased, and positron emission tomography showed abnormal uptake of <sup>18</sup>F-fluorodeoxyglucose in these lesions. Considering this evidence, the cystic lesions were diagnosed as multiple lung metastases. Various differential diagnoses should be considered when diffuse cystic lesions are found in the lungs after the administration of immune checkpoint inhibitors.

Journal

Case Reports in Oncology – Karger

Published: Jan 1, 2021

Keywords: Non-small cell lung cancer; Diffuse cysts; Immune checkpoint inhibitor; Radiology; Diagnosis

References

  • Cystic lung diseases: algorithmic approach
    Raoof, S; Bondalapati, P; Vydyula, R; Ryu, JH; Gupta, N; Raoof, S
  • A phase 2 study of adjuvant carboplatin plus S-1 followed by maintenance S-1 therapy for patients with completely resected stage II/IIIA non-small cell lung cancer-Japanese Northern East Area Thoracic Surgery Study Group JNETS1302 study
    Hasegawa, T; Suzuki, H; Abe, J; Sakurada, A; Endo, C; Sato, N
  • Rare occurrence of cavitation of lung metastases following effective targeted therapy: a case report
    Song, J; Yu, J; Ma, Z; Lu, S
  • Diffuse cystic lung adenocarcinoma: a case report and literature review
    Wang, SB; Tu, JW; Dong, K
  • Rapidly progressive diffuse cystic lesions as a radiological hallmark of lung adenocarcinoma
    Zhang, J; Zhao, YL; Ye, MX; Sun, G; Wu, H; Wu, CG
  • Nivolumab-induced pneumonitis complicated by cyst formation
    Gorospe, L; Ayala-Carbonero, AM; Olmedo-García, ME; Gómez-Rueda, A; Palka, M; Mezquita, L
  • Lung tissue injury as an atypical response to nivolumab in non-small cell lung cancer
    Rampinelli, C; Spitaleri, G; Passaro, A; Pochesci, A; Ancona, E; De Marinis, F
  • RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
    Xiao, Y; Yu, S; Zhu, B; Bedoret, D; Bu, X; Francisco, LM